Frier Levitt Explores '340B & Telehealth: Key Regulatory Considerations' in On-Demand Webinar

Tune in for an overview of the 340B Drug Pricing Program and its intersection with innovative telehealth arrangements. Presented by Frier Levitt attorneys Jesse Dresser, Arielle Miliambro, and Maria Stahl, this webinar highlights the complex regulatory landscape and underscores the importance for stakeholders to stay informed about legal developments and proposed changes. Key Takeaways: • 340B Program and Patient Eligibility: Understand the criteria for hospital and non-hospital grantee Covered Entities and patient eligibility, including compliance with diversion prohibitions. • Impact of Genesis Health Care Inc. v. Becerra: Learn about the ruling's implications and HRSA's continued enforcement of the 1996 Guidance on patient eligibility, and considerations when applied to telemedicine encounters. • Proposed Legislative Changes: Follow pending legislation, including the SUSTAIN 340B Act, and explore the proposed changes to the definition of an "eligible patient" and how it may affect prescription-by-prescription eligibility. • Contract Pharmacies: Gain insights into the impact of recent court decisions and state legislation on contract pharmacies, including manufacturer restrictions and 340B-specific reimbursement policies by PBMs. • Non-Hospital Grantee Covered Entities and Regulatory Issues: Engage in a discussion regarding the increase in Non-Hospital Grantee Covered Entities and the accompanying regulatory considerations